|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cuzick J, Thorat MA, Andriole G, Brawley
OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et
al: Prevention and early detection of prostate cancer. Lancet
Oncol. 15:e484–e492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen FZ and Zhao XK: Prostate cancer:
Current treatment and prevention strategies. Iran Red Crescent Med
J. 15:279–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steinfeld I, Navon R, Ach R and Yakhini Z:
miRNA target enrichment analysis reveals directly active miRNAs in
health and disease. Nucleic Acids Res. 41:e452013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Medina PP and Slack FJ: microRNAs and
cancer: An overview. Cell Cycle. 7:2485–2492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Kouwenhove M, Kedde M and Agami R:
MicroRNA regulation by RNA-binding proteins and its implications
for cancer. Nat Rev Cancer. 11:644–656. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dalmay T: Mechanism of miRNA-mediated
repression of mRNA translation. Essays Biochem. 54:29–38. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park JK, Henry JC, Jiang J, Esau C, Gusev
Y, Lerner MR, Postier RG, Brackett DJ and Schmittgen TD: miR-132
and miR-212 are increased in pancreatic cancer and target the
retinoblastoma tumor suppressor. Biochem Biophys Res Commun.
406:518–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scapoli L, Palmieri A, Lo Muzio L,
Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M and
Carinci F: MicroRNA expression profiling of oral carcinoma
identifies new markers of tumor progression. Int J Immunopathol
Pharmacol. 23:1229–1234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wada R, Akiyama Y, Hashimoto Y, Fukamachi
H and Yuasa Y: miR-212 is downregulated and suppresses
methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J
Cancer. 127:1106–1114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Incoronato M, Garofalo M, Urso L, Romano
G, Quintavalle C, Zanca C, Iaboni M, Nuovo G, Croce CM and
Condorelli G: miR-212 increases tumor necrosis factor-related
apoptosis-inducing ligand sensitivity in non-small cell lung cancer
by targeting the antiapoptotic protein PED. Cancer Res.
70:3638–3646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mehta A, Mann M, Zhao JL, Marinov GK,
Majumdar D, Garcia-Flores Y, Du X, Erikci E, Chowdhury K and
Baltimore D: The microRNA-212/132 cluster regulates B cell
development by targeting Sox4. J Exp Med. 212:1679–1692. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morgan R, Boxall A, Bhatt A, Bailey M,
Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H,
et al: Engrailed-2 (EN2): A tumor specific urinary biomarker for
the early diagnosis of prostate cancer. Clin Cancer Res.
17:1090–1098. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bose SK, Bullard RS and Donald CD:
Oncogenic role of engrailed-2 (en-2) in prostate cancer cell growth
and survival. Transl Oncogenomics. 3:37–43. 2008.PubMed/NCBI
|
|
19
|
Marszałł MP, Sroka W, Adamowski M, Słupski
P, Jarzemski P, Siódmiak J and Odrowąż-Sypniewska G: Engrailed-2
protein as a potential urinary prostate cancer biomarker: A
comparison study before and after digital rectal examination. Eur J
Cancer Prev. 24:51–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McGrath SE, Michael A, Morgan R and Pandha
H: EN2: A novel prostate cancer biomarker. Biomarkers Med.
7:893–901. 2013. View Article : Google Scholar
|
|
21
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs as biomarkers for diagnosis, prognosis and theranostics
in prostate cancer. Int J Mol Sci. 17:4212016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ha TY: MicroRNAs in human diseases: From
cancer to cardiovascular disease. Immune Netw. 11:135–154. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baranwal S and Alahari SK: miRNA control
of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290.
2010.PubMed/NCBI
|
|
26
|
Zhang C, Chen X, Chen X, Wang X, Ji A,
Jiang L, Sang F and Li F: miR-135a acts as a tumor suppressor in
gastric cancer in part by targeting KIFC1. Onco Targets Ther.
9:3555–3563. 2016.PubMed/NCBI
|
|
27
|
Zhao XY and Shao K: Roles of MicroRNA-21
in the pathogenesis of insulin resistance and diabetic
mellitus-induced non-alcoholic fatty liver disease. Zhongguo Yi Xue
Ke Xue Yuan Xue Bao. 38:144–149. 2016.(In Chinese). PubMed/NCBI
|
|
28
|
Yu G, Zhan X, Zhang Z and Li Y:
Overexpression of miR-125b promotes apoptosis of macrophages. Xi
Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:958–962. 2016.(In Chinese).
PubMed/NCBI
|
|
29
|
Han R, Ji X, Rong R, Li Y, Yao W, Yuan J,
Wu Q, Yang J, Yan W, Han L, et al: miR-449a regulates autophagy to
inhibit silica-induced pulmonary fibrosis through targeting Bcl2. J
Mol Med (Berl). 94:1267–1279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bouyssou JM, Manier S, Huynh D, Issa S,
Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer
metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI
|
|
31
|
Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H,
Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic
cancer cell growth and invasion by targeting the hedgehog signaling
pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tu H, Wei G, Cai Q, Chen X, Sun Z, Cheng
C, Zhang L, Feng Y, Zhou H, Zhou B, et al: MicroRNA-212 inhibits
hepatocellular carcinoma cell proliferation and induces apoptosis
by targeting FOXA1. Onco Targets Ther. 8:2227–2235. 2015.PubMed/NCBI
|
|
33
|
Ramalinga M, Roy A, Srivastava A,
Bhattarai A, Harish V, Suy S, Collins S and Kumar D: MicroRNA-212
negatively regulates starvation induced autophagy in prostate
cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis
and cellular senescence. Oncotarget. 6:34446–34457. 2015.PubMed/NCBI
|
|
34
|
Borrego-Diaz E, Powers BC, Azizov V,
Lovell S, Reyes R, Chapman B, Tawfik O, McGregor D, Diaz FJ, Wang
X, et al: A potential regulatory loop between Lin28B:miR-212 in
androgen-independent prostate cancer. Int J Oncol. 45:2421–2429.
2014.PubMed/NCBI
|
|
35
|
Zhao JL, Zhang L, Guo X, Wang JH, Zhou W,
Liu M, Li X and Tang H: miR-212/132 downregulates SMAD2 expression
to suppress the G1/S phase transition of the cell cycle and the
epithelial to mesenchymal transition in cervical cancer cells.
IUBMB Life. 67:380–394. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu H, Li C, Shen C, Yin F, Wang K, Liu Y,
Zheng B, Zhang W, Hou X, Chen X, et al: miR-212-3p inhibits
glioblastoma cell proliferation by targeting SGK3. J Neurooncol.
122:431–439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Killick E, Morgan R, Launchbury F,
Bancroft E, Page E, Castro E, Kote-Jarai Z, Aprikian A, Blanco I,
Clowes V, et al: Role of Engrailed-2 (EN2) as a prostate cancer
detection biomarker in genetically high risk men. Sci Rep.
3:20592013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee S, Jo H, Her J, Lee HY and Ban C:
Ultrasensitive electrochemical detection of engrailed-2 based on
homeodomain-specific DNA probe recognition for the diagnosis of
prostate cancer. Biosens Bioelectron. 66:32–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Y, Liu H, Lai C, Su Z, Heng B and Gao
S: Repression of engrailed 2 inhibits the proliferation and
invasion of human bladder cancer in vitro and in
vivo. Oncol Rep. 33:2319–2330. 2015.PubMed/NCBI
|
|
40
|
Abollo-Jiménez F, Campos-Sánchez E,
Toboso-Navasa A, Vicente-Dueñas C, González-Herrero I,
Alonso-Escudero E, González M, Segura V, Blanco O, Martínez-Climent
JA, et al: Lineage-specific function of Engrailed-2 in the
progression of chronic myelogenous leukemia to T-cell blast crisis.
Cell Cycle. 13:1717–1726. 2014. View
Article : Google Scholar : PubMed/NCBI
|
